Equity Overview
Price & Market Data
Price: $9.37
Daily Change: +$0.23 / 2.45%
Daily Range: $9.30 - $9.61
Market Cap: $149,891,888
Daily Volume: 13,518
Performance Metrics
1 Week: -5.59%
1 Month: 11.28%
3 Months: 73.20%
6 Months: 5.04%
1 Year: 84.45%
YTD: 83.73%
Company Details
Employees: 32
Sector: Health technology
Industry: Biotechnology
Country:
Details
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph nodetargeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph nodetargeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph nodetargeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.